In pregnant rats, a significant decrease in myometrial relaxin family peptide receptor 1 (RXFP1) expression, indicative of a functional relaxin withdrawal for activation of myometrial contractions, occurs in late gestation and during spontaneous labor. This coincides with the highest level of circulating relaxin and a decrease in progesterone. We investigated the potential regulatory role of these two systemic factors on myometrial RXFP1 expression by examining the effects of the antiprogestin RU486 and a monoclonal antibody against rat relaxin (MCA1) in pregnant rats. Rats were injected with RU486 on Gestational Day (GD) 7, 16, or 19 and were killed on GD 8, 17, or 20. RU486 caused a significant reduction in myometrial RXFP1. Plasma progesterone and 17beta-estradiol levels were increased in RU486-treated animals compared with controls. RU486 treatment also caused significant increases in myometrial Esr1 and Vegf and a decrease in Esr2. MCA1 was administered i.v. to rats from GD 17 to GD 19. On GD 20, no significant effect of MCA1 treatment on myometrial RXFP1 expression was observed compared with controls. Furthermore, there was no change in Esr1 or Esr2. A significant reduction in myometrial Vegf, however, was observed. We suggest that blocking progesterone action with RU486 increases plasma 17beta-estradiol and myometrial Esr1 and results in decreased RXFP1 expression. In summary, myometrial RXFP1 expression is mediated mainly by progesterone and not circulating relaxin in pregnant rats.
INTRODUCTION
The peptide hormone relaxin is thought to inhibit spontaneous myometrial contractions during pregnancy and prevent the premature activation of contractile-associated proteins (CAPs), such as oxytocin [1] [2] [3] . Relaxin treatment abolishes the plateau component of the action potential, characteristic of the electrical activity of the circular myometrium, thus reducing the contractile response [4] . In addition, relaxin decreases oxytocin-stimulated myometrial contractions by inhibiting phosphatidyl-inositol phosphate turnover and suppressing phospholipase C [5] . These actions of relaxin are now known to be mediated through a leucine-rich repeat containing heterotrimeric guanine nucleotide-binding, G protein-coupled receptor, known as relaxin family peptide receptor 1 (RXFP1). We demonstrated significant decreases in myometrial Rxfp1 gene and protein expression in late gestation and during spontaneous labor in the rat and proposed that the RXFP1 receptor down-regulation is a mechanism of functional relaxin withdrawal necessary for the activation of CAPs in the myometrium [6] .
In the rat, the late gestation decrease in myometrial Rxfp1 is partially mediated by the presence of the fetal-placental unit [6] . However, it also coincides with the decline in circulating progesterone levels and with the highest plasma relaxin concentrations [7] . To date, very little is known about the in vivo regulation of RXFP1. In vitro studies have found that medroxyprogesterone acetate is required to stimulate RXFP1 expression in nondecidualized human endometrial stromal cells and, to a lesser extent, in glandular and decidual cells [8] . Further indirect evidence for progesterone regulation of relaxin receptors was shown in marmoset monkeys with biotinylated relaxin to measure relaxin-binding sites in the endometrium at different phases of the cycle. Relaxin-binding sites in the stroma increased after ovulation during the secretory phase, presumably correlated with high progesterone [9] . These studies, however, do not provide insight regarding the effects of progesterone withdrawal on myometrial RXFP1 expression in late gestation.
Relaxin-binding studies have shown an inhibitory effect of relaxin on its own receptor in the rat myometrium at term [10] . Rxfp1 expression is significantly increased in the cervix and myometrium of pregnant relaxin mutant (Rln À/À ) mice on Gestational Day (GD) 18.5 [11, 12] . Conversely, relaxin treatment in pregnant Rln À/À mice decreased cervical and myometrial Rxfp1 [11, 12] and reduced cervical, but not myometrial, Rxfp1 expression in the neonatal pig [13] . Therefore, it is possible that high circulating concentrations of endogenous relaxin in late gestation mediate the decrease in RXFP1 expression in the rat myometrium.
The overall aim of the present study was to test the hypothesis that the decrease in myometrial RXFP1 expression in late gestation results from a combination of progesterone withdrawal and increased circulating relaxin concentrations. This was achieved by determining the effects of the antiprogestin compound RU486 and of a neutralizing monoclonal antibody against rat relaxin (MCA1) on myometrial RXFP1 gene and protein expression in the pregnant rat. We extended our analysis to include estrogen receptors (Esr1 and Esr2) and vascular endothelial growth factor (Vegf) gene expression because of the known mechanistic interactions between relaxin and these factors in the rat, rhesus monkey, and pig uterus [13] [14] [15] .
MATERIALS AND METHODS

Animal Models
All animal experiments were conducted with ethical approval from each of the relevant institutional animal experimentation ethics committees. Two groups of Wistar rats were used for different aspects of the present study. The first group of rats was used in a pilot study (group A; Charles River Co.) and was housed at the Samuel Lunenfeld Research Institute under standard laboratory conditions with access to Purina Rat Chow (Ralston Purina) and water ad libitum. The day a vaginal plug was observed was designated as GD 1. Rats gave birth on the morning of GD 23. The second group of rats (group B; Animal Research Facility) was needed to expand the study to include different treatment groups, to increase the sample size, and to allow protein analysis. These rats were housed under similar laboratory conditions in the Biological Research Facility (Departments of Pharmacology and Physiology, The University of Melbourne). The presence of sperm in the vaginal smear was taken as GD 1; rats gave birth on the morning of GD 22.
Experimental Design RU486-induced preterm labor. A pilot study was first conducted using the group A rats. We were provided with myometrial RNA collected from pregnant rats treated with RU486 (10 mg/kg in 0.5 ml of corn oil; SigmaAldrich) or vehicle at 1000 h on GD 19 (n ¼ 4 per treatment group) by Dr. Oksana Shynlova and Prof. Stephen Lye (Samuel Lunenfeld Research Institute). Myometrial tissues were collected after visible delivery of at least one pup on GD 20 or 24 h after treatment. Because we saw an effect of RU486 treatment on myometrial Rxfp1 gene expression, we expanded the study to include two further treatment groups, with larger sample sizes and a more comprehensive analysis of protein and steroid hormone concentrations using group B rats. These rats were treated with a single subcutaneous injection of RU486 (10 mg/kg in 0.5 ml of corn oil containing 10% ethanol; SigmaAldrich) or vehicle between 1100 and 1200 h either on GD 7 or GD 16 (n ¼ 6-7 per treatment group). Approximately 24 h after RU486 or vehicle injection, rats were killed with an intraperitoneal overdose of ketamine (100 mg/kg) or Ilium Xylazil-20 (30 mg/kg; Troy Laboratories Pty., Ltd.) on GD 8 and GD 17, respectively. Blood was collected by cardiac puncture and centrifuged at 1000 3 g for 15 min. Plasma was collected, frozen, and stored at À808C for steroid assay. The uteri were removed immediately after the animal was killed, and the decidualized endometrium and fetal-placental units were removed from the uterine wall as described previously [6] . The myometrium was then snap-frozen in liquid nitrogen and stored at À808C until RNA extraction.
Treatment with MCA1. On GD 14, group B rats were initially anesthetized with 4.2% fluorothane and then maintained at 2.9% (Univentor 400; AgnThos). Once anesthetized, rats were chronically instrumented using sterile techniques with a tygon catheter (polyvinyl chloride tubing, 1.50 3 1.00 mm; Microtube Extrusions) implanted in the right jugular vein with the tip located at the junction of the anterior vena cava and right atrium. The catheter was tunneled to the dorsum, and animals were allowed to recover overnight. From GD 15 onward, the catheter was flushed twice daily with heparinized saline. Neutralizing monoclonal antibodies against rat relaxin (MCA1; n ¼ 8 pregnant rats) or control antibodies against fluorescein (MCAF; n ¼ 8 pregnant rats) were administered daily between 0900 and 1100 h for 3 days beginning on GD 17. Each dose of 5 mg of antibody in 0.5 ml of PBS was infused over 5 min into the jugular catheter. The dose and route of antibody administration were the same as those previously reported [16] . Animals were killed on the morning of GD 20, and tissues were collected as described previously. In addition, the cervix was weighed and fixed in 10% neutral buffered formalin for histological analysis.
RNA extraction and quantitative PCR. Total RNA was extracted from frozen tissues using either Trizol (Gibco BRL) and RNeasy Mini kits (Qiagen) or Micro-to-Midi Total RNA Purification System kits (Invitrogen). The RNA was then treated with 2 U of DNase I to remove genomic DNA contamination. RNA concentrations were determined using a Bio-Rad Smart Spec 3000 with A 260 :A 280 absorbance ratios of greater than 1.9. First-strand cDNA synthesis used 1 lg of total RNA in a 20-ll reaction, with random hexamers (50 ng/ll) and 200 U of SuperScript III (Invitrogen). Relative quantification of Rxfp1 gene expression used the comparative cycle threshold (DDC T ) method with ribosomal Rn18s as the reference gene as previously described [6, 17] . We also measured Esr1, Esr2, and Vegf mRNA expression. Rat specific forward/ reverse primers and 6-carboxy fluorescein-labeled TaqMan probes for these genes were purchased from Biosearch Technologies. Quantitative RT-PCR was performed on the Rotor-Gene v6 (Corbett Research Pty Ltd.) in 20-ll volumes in triplicate containing Sensimix (Quantace Pty Ltd.). Myometrial Rn18s expression did not differ significantly (P . 0.05) between treatment groups and so was a valid reference gene in this analysis. The mean Rn18s C T value of each triplicate was subtracted from the corresponding mean gene-of-interest C T triplicate value to normalize gene expression to the reference gene. These normalized data were then presented as a value relative to control rats and plotted with the SD.
Western Blot Analysis
The preparation of tissues and Western blot procedures were as described previously [6] . Seventy-five micrograms of protein were loaded into 30-ll well Pre-Cast 7.5% Tris-glycine/SDS gels (Bio-Rad Australia). The immunoblots were cut in half, and the upper half was incubated overnight at 48C with 0.8 lg/ ml of purified rabbit anti-RXFP1 antibody 107 (raised against amino acid residues 107-119 of the rat RXFP1 protein), whereas the lower half was incubated in horseradish peroxidase (HRP)-conjugated tubulin (1:20 000; Abcam) for 1 h to demonstrate equal loading of protein. Negative-control blots were incubated with purified rabbit immunoglobulin (Ig) G (DAKO) diluted in the same manner as the primary antibody. After washes in Tris-buffered saline (10 mM Tris and 150 mM NaCl, pH 7.4) containing 0.05% Tween 20 (TTBS), blots were incubated for 1 h at room temperature with HRP-conjugated goat anti-rabbit secondary antibody (Bio-Rad Australia) diluted 1:50 000 in TTBS. The chemiluminescent substrate reagent ECL Plus (Amersham, GE Healthcare Bio-Sciences Pty Ltd.) was applied to the blots for 5 min for RXFP1 and 1 min for tubulin. The membrane was viewed in the ChemiDoc XR Gel Documentation System (Bio-Rad Australia) for signal detection. Data were quantified using densitometry software (Quantity One; Bio-Rad Australia), with fixed corrections to background and volume (the sum of the intensities of the pixels inside the boundary area measured in mm 2 ) so that an equal area was measured from each band. Tubulin pixel density (intensity/mm 2 as determined by the software) did not differ significantly (P . 0.05) between treatment groups in either experiment. For each myometrial sample, the tubulin pixel density value was divided by the corresponding RXFP1 pixel density value to normalize protein expression to tubulin. These normalized data were then averaged for each treatment group and presented as a value relative to GD 8 vehicle-treated rats and plotted with the SEM.
Steroid Assays
Plasma progesterone (DPC Coat-A-Count Radioimmunoassay; Diagnostic Products Corporation) and 17b-estradiol (DSL Radioimmunoassay; Diagnostic Systems Laboratories) concentrations were measured using rat-specific, commercially available kits according to the manufacturer's instructions. The minimum detectable concentrations of progesterone and 17b-estradiol were 0.02 ng/ml and 2.2 pg/ml, respectively. The intra-assay coefficient of variation was 10.5% at 67% binding and 13.9% at 64% binding for the two assays.
Statistical Analysis
Significant differences in myometrial Rxfp1, Esr1, Esr2, and Vegf gene expression and RXFP1 protein levels between treatments on GD 8 and GD 17 were analyzed with two-way ANOVA, with unpaired Student t-test for post hoc comparisons (IBM SPSS Statistics). An unpaired Student t-test was used to evaluate differences between vehicle and RU486 treatment on GD 20. Myometrial gene and protein expression data from the MCA1 experiment was analyzed by one-way ANOVA with Tukey post hoc comparisons (IBM SPSS Statistics). Differences were considered to be statistically significant when P was less than 0.05.
RESULTS
RU486-Induced Preterm Labor
Rats treated with RU486 on GD 7, 16, or 19 either aborted or showed signs of disrupted pregnancy approximately 24 h later, on GD 8, 17, or 20, respectively. None of the controls underwent spontaneous labor. A significant increase in cervical and uterine wet weight was observed on GD 8 in the RU486-treated animals compared with vehicle-treated controls (Table  1) . RU486 treatment on GD 8, 17, and 20 caused a significant decrease in Rxfp1 gene expression in the myometrium 826 VODSTRCIL ET AL. compared to rats treated with vehicle (Fig. 1, A and B) . For the purpose of analysis, only the GD 8 and GD 17 groups could be compared directly, because they were the same cohort of experimental animals. We observed a significantly greater reduction in Rxfp1 expression in the RU486-treated rats on GD 17 compared with those treated on GD 8 (Fig. 1A) . Western blot analysis demonstrated a major immunoreactive protein of approximately 75 kDa and a fainter, 60-kDa protein (Fig. 1C) . As shown previously [6] , both immunoreactive proteins were markedly diminished when rabbit IgG was substituted for the primary antibody. RU486 treatment caused a significant decrease in RXFP1 protein compared to controls on GD 8 but had no effect on GD 17 (Fig. 1D ). However, a significant reduction in myometrial RXFP1 protein expression was found on GD 17 compared with GD 8 in the vehicle-treated controls (Fig. 1D) .
Administration of RU486 resulted in significantly higher Esr1 expression compared with vehicle-treated controls in all three gestational groups (Fig. 2, A and B) . On GD 17, significantly less Esr2 expression was observed compared with that on GD 8 in vehicle-treated rats. Esr2 expression was also significantly lower in rats treated with RU486 on GD 8 but was higher on GD 17 and 20 (Fig. 2, C and D) . It is important to note that to obtain C T values of less than 35, it was necessary to use undiluted cDNA. All other genes used a 1:16 dilution. Therefore, the efficiencies between Esr1 and Esr2 were different, and it can be concluded that Esr2 expression was substantially lower compared with all other genes. Because Esr1 is a known regulator of Vegf transcription, we also measured myometrial Vegf mRNA levels. GD 17 rats had significantly higher Vegf levels compared with GD 8 rats, regardless of treatment with vehicle or RU486 (Fig. 2E) . On GD 8, RU486 treatment resulted in significantly higher Vegf expression versus controls but had no significant effect on GDs 17 and 20 (Fig. 2, E and F) .
Treatment with RU486 had no effect on circulating progesterone levels on GD 8 but caused a significant increase on GD 17 compared with vehicle-treated controls (Fig. 3A) . Plasma 17b-estradiol concentrations were significantly higher in vehicle-treated animals on GD 17 compared with GD 8 rats and significantly increased at both stages of gestation in RU486-treated animals (Fig. 3B) .
Treatment with MCA1
Neutralizing circulating relaxin with the MCA1 antibody between GD 17 and GD 20 caused a significant decrease in pubic symphysis length compared with MCAF-treated controls (Table 2) . Although the cervix weight was not affected by MCA1 treatment as previously reported [18, 19] , fewer and smaller luminal involutions were found in MCA1-treated rats (data not shown), confirming efficacy of the relaxin-neutralizing antibody. No significant effect of MCA1 treatment on the number of viable young or the number of resorbed fetuses was observed on GD 20. Rxfp1 expression in the myometrium was significantly lower in both MCAF-and MCA1-treated rats on GD 20 compared with nonpregnant rats (Fig. 4A) . However, no effect of MCA1 treatment was found on Rxfp1 mRNA compared to the MCAF control (Fig. 4A) . This was confirmed at the protein level by Western blot analysis (Fig. 4, B and C) . Myometrial Esr1 levels did not differ between nonpregnant rats and those treated with MCAF or MCA1 (Fig. 5A) . In contrast, Esr2 expression was significantly lower in both MCAF-and MCA1-treated rats on GD 20 compared with nonpregnant rats (Fig. 5B) . However, no effect of MCA1 treatment was found. We also analyzed myometrial Vegf expression and observed 
REGULATION OF MYOMETRIAL RXFP1
significantly higher expression on GD 20 in MCAF-and MCA1-treated rats compared to nonpregnant rats. Interestingly, neutralizing circulating relaxin with MCA1 significantly reduced Vegf expression compared with MCAF controls (Fig.  5C ), although not to nonpregnant levels. Plasma progesterone and 17b-estradiol concentrations did not differ between the treatment groups (data not shown).
DISCUSSION
We previously demonstrated that RXFP1 expression in the myometrium decreases in late gestation and during spontaneous labor in rats [6] . The aim of the present study was to investigate if this is mediated by a decrease in progesterone or by high circulating concentrations of the endogenous ligand relaxin. Our experimental design enabled us to investigate the contribution of both of these systemic hormones on RXFP1 expression because of their different concentrations at various stages of gestation. Plasma relaxin is first detected in the rat after GD 10 and reaches maximal levels at term [7] , whereas progesterone is detectable throughout the whole of gestation, with highest concentrations from GD 17 to GD 19 before withdrawal at parturition. Blocking the action of progesterone with RU486 in early, mid, and late gestation caused a significant decrease in myometrial Rxfp1 expression. It was important to substantiate the gene expression data and demonstrate parallel changes in RXFP1 protein. As shown previously [6] , two RXFP1 proteins of approximately 75 and 60 kDa were detected in the rat myometrium with the anti-rat RXFP1 antibody 107 under reducing conditions. Our interpretation is that the former RXFP1 protein represents a mature form of the receptor, whereas the smaller, 60-kDa protein could either be a precursor receptor or a deglycosylated form. Decreased expression of the 75-kDa RXFP1 protein was (C and D) , and Vegf (E and F) gene expression in rats treated with vehicle (closed bar) or RU486 (open bar) on GD 8 (n ¼ 6-7), GD 17 (n ¼ 6-7), and GD 20 (n ¼ 4). Data are presented relative to GD 8 controls (A, C, and E) and GD 20 controls (B, D, and F) and are presented as the mean 6 SD. *Significant difference versus controls (P , 0.05), # significant difference versus GD 8 (P , 0.05), and^significant difference versus GD 8 controls (P , 0.05).
FIG. 2. Relative myometrial
828 observed in RU486-treated rats on GD 8. This suggests that progesterone is important for maintaining expression of myometrial RXFP1 during early pregnancy and that progesterone withdrawal at the end of pregnancy contributes to the decline in RXFP1. It should be noted that we only addressed myometrial RXFP1 in the present study and that the effects of RU486 on RXFP1 receptor expression in the endometrium (stroma and epithelium) and cervical tissues could be different. In vitro studies also report a positive effect of progestin treatment on undifferentiated human endometrial stromal cells and, to a lesser extent, in glandular and decidualized cells [8] , implying that progesterone may have common stimulatory effects in all compartments of the uterus. One limitation of our findings is that we did not assess the maximal binding capacity of RXFP1 at the cell surface after RU486 treatment. This is difficult to achieve because of the unavailability of ligands specific for the different receptor subtypes, which we know are expressed in the rat myometrium [17] . Nevertheless, our in vivo study is, to our knowledge, the first to show that 
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829 progesterone is a major positive regulator of myometrial Rxfp1 gene and protein expression during pregnancy. Although a decrease in Rxfp1 gene expression was observed in the RU486-treated rats on GD 17, this was not paralleled by a decrease in RXFP1 protein. An opposing effect of RU486 on GDs 17 and 20 compared with GD 8 was also observed in both Esr2 and Vegf expression, suggesting a disruption of downstream posttranslational pathways involving estrogen. We speculate that the increase in myometrial Esr2 in RU486-treated rats on GDs 17 and 20 leads to increased formation of heterodimers with ESR1, thereby preventing the active ESR1 homodimer from activating estrogen response elements (EREs) or ERE-independent pathways [20, 21] . So, despite the increase in plasma 17b-estradiol, activation of ESR1 was insufficient to cause the decrease in RXFP1. This would also explain why no increase in myometrial Vegf was observed in the RU486-treated rats and why uterine and cervical wet weights were not different between RU486-and vehicle-treated animals on GD 17. On GD 8, RU486 clearly increases plasma 17b-estradiol and Esr1 but also decreases Esr2, so a decrease in RXFP1 and an increase in Vegf do occur. This implies that estrogen regulates RXFP1 protein, but not necessarily Rxfp1 gene expression, in the rat myometrium.
The significant increase in plasma progesterone concentrations in the RU486-treated rats on GD 17 may be responsible for the increase in myometrial Esr2 [22, 23] . An alternative explanation for the different effects of RU486 treatment on RXFP1 could be the higher circulating levels of relaxin on GD 17 compared with GD 8. Our original hypothesis was that high circulating relaxin down-regulates its own receptor. However, neutralizing circulating relaxin with MCA1 had no effect on myometrial Rxfp1 gene or protein expression, suggesting that high circulating relaxin concentrations do not mediate the decrease in RXFP1 expression at the end of pregnancy. This is in contrast to the work in Rln À/À mice, which have increased Rxfp1 expression in the myometrium and cervix [12, 24] . Earlier binding studies found an inhibitory effect of relaxin on its own receptor in the rat myometrium at term [10] , and relaxin treatment in pregnant Rln À/À mice caused a significant decrease in cervical and myometrial Rxfp1 expression [11, 12] . However, important differences exist between the two rodent models of relaxin deficiency. Rln À/À mice cannot synthesize relaxin and, therefore, completely lack relaxin. In the MCA1-treated rats, circulating relaxin has been neutralized and is unable to activate RXFP1, but these rats continue to synthesize relaxin from the ovaries. Relaxin gene transcripts have also been demonstrated in the rat uterus and placenta [25] , so it is possible that local production of relaxin in these tissues is not compromised by MCA1. In addition, our experimental design involved treating rats between GD 17 and GD 20, which was a much shorter treatment period than in previous studies [16, 18, 19, 26] and did not produce the characteristic decrease in cervix wet weight. However, our treatment reduced the length of the pubic symphysis and modestly reduced cervical remodeling, suggesting that our MCA1 treatment had biological effects but that these effects were not as profound as those in previous studies. To support our view that MCA1 was effective in our experiment, a significant reduction in Vegf expression was observed in the myometrium of MCA1-treated dams compared to the MCAF controls. This was not associated with a change in plasma progesterone or 17b-estradiol, because concentrations of both steroids were unaffected by MCA1 treatment. In summary, our data show that MCA1 treatment for 3 days had no effect on myometrial Rxfp1 gene and protein expression, although it decreased Vegf mRNA. This suggests that increased circulating relaxin is not a major regulator of 830 myometrial RXFP1 in late gestation and does not account for the increase in RXFP1 protein on GD 17 in RU486-treated rats.
Our data provide new insights regarding the potential mechanistic pathways leading to RXFP1 down-regulation in late gestation and suggest the effects of RU486 on RXFP1 could be the result of additional changes in the levels of other hormones besides the direct effect of progesterone withdrawal. Of significance is the increase in progesterone and 17b-estradiol in the RU486-treated rats. A similar effect of RU486 was reported by Fang et al. [27] and Garfield et al. [28] , although the increase in progesterone was not significant in the latter study. RU486 stimulates ovarian 3b-hydroxysteroid dehydrogenase activity yet inhibits progesterone secretion between GD 7 and GD 14. It has the reverse effect, however, from GD 15 to GD 20 and stimulates progesterone [29] . This may explain why increases in plasma progesterone were only seen after RU486 treatment on GD 17 in our study. Treatment with RU486 increased 17b-estradiol on GD 8 and GD 17, and this is consistent with previous work [27, 28] . Our study also reported increased myometrial Esr1 expression after RU486 treatment. These data contradict the findings of Fang et al. [27] , who reported that RU486 had no significant effect on uterine Esr mRNA concentrations at numerous time points (0, 6, 12, 48, and 72 h) after initial treatment, although a trend for ESR levels to increase after 24 and 48 h was found. We also reported increased uterine wet weight and Vegf expression in the RU486-treated rats, which are indicators of enhanced 17b-estradiol action and increased ESRs in these animals.
Overall, the findings of the present study demonstrate that blocking the action of progesterone leads to an increase in 17b-estradiol levels and myometrial Esr1 expression and that this is a potential mechanism by which RXFP1 is down-regulated in the myometrium during late pregnancy. However, these effects likely are dependent on a decrease in myometrial Esr2, at least at the protein level. Previous work has shown that 17b-estradiol regulates relaxin receptor expression. Uterine [ 125 I]relaxin-binding sites were highest during estrus and proestrus and could not be detected during metestrus and diestrus [10] . Furthermore, ovariectomy decreased, whereas 17b-estradiol administration increased, relaxin binding to the rat myometrium [10] . Similarly, quantitative receptor autoradiography studies showed 17b-estradiol treatment in nonpregnant rats increased density of relaxin-binding sites in the uterus [30] . In addition, Rxfp1 gene expression increased after estradiol valerate treatment from birth in the uterus of Postpartum Day 2 pigs, again indicating the positive effects of 17b-estradiol on Rxfp1 [13] . Treatment of human lower uterine segment fibroblasts in vitro with estrogen also increases Rxfp1 mRNA expression [31] . This contradicts the data in the present study, because RU486 treatment increased 17b-estradiol and Esr1 but resulted in a decrease in RXFP1. In the present study, however, we used pregnant rats, which have a very different endogenous steroid profile compared with neonatal pigs and nonpregnant ovariectomized rats, and this could account for the different effects of 17b-estradiol on myometrial RXFP1 expression. In addition, as we have reported previously [6] , the presence of the fetal-placental unit is associated with a reduction in RXFP1 expression. Therefore, we propose that the combination of progesterone withdrawal, high circulating 17b-estradiol, and increased myometrial Esr1 activation, along with decreased myometrial Esr2 and maximal mechanical stretch of uterine walls imposed by growing fetuses, triggers the down-regulation in RXFP1 during late gestation in the rat.
